Olvidé mi contraseña
Asóciese a SIIC en Internet para utilizar sin límites tanto siicsalud como la totalidad de los servicios bibliográficos de la institución.
Lectura recomendada:
Comparison of Imatinib 400 mg and 800 mg Daily in the Front-Line Treatment of High-Risk, Philadelphia-Positive Chronic Myeloid Leukemia: a European LeukemiaNet Study
Blood, 113(19):4497-4504
Lectura recomendada:
Efficacy of Azacitidine Compared with That of Conventional Care Regimens in the Treatment of Higher-Risk Myelodysplastic Syndromes: a Randomised, Open-Label, Phase III Study
Lancet Oncology, 10(3):223-232
Lectura recomendada:
Management of Acute Promyelocytic Leukemia: Recommendations from an Expert Panel on Behalf of the European LeukemiaNet
Blood, 113(9):1875-1891
Lectura recomendada:
Appraisal of Immune Response in Lymphoproliferative Syndromes: A systematic Review
Critical Reviews in Oncology Hematology, 70(2):103-113
Lectura recomendada:
Six-Year Follow-Up of Patients Receiving Imatinib for the First-Line Treatment of Chronic Myeloid Leukemia
Leukemia, 23(6):1054-1061
Lectura recomendada:
Evaluating the Incidence of Leukopenia and Neutropenia with Valproate, Quetiapine, or the Combination in Children and Adolescents
Annals of Pharmacotherapy, 43(5):822-830
¿Qué hallazgos en el extendido de sangre periférica son orientadores de la presencia de un síndrome mielodisplásico?
Introducción:
Frente a un hemograma inicial que indica la presencia de anemia macrocítica, para establecer el diagnóstico se sugiere la realización de un hemograma para confirmar los valores iniciales y establecer si las alteraciones son estables o progresivas, un extendido de sangre periférica, determinaciones de vitamina B12 y ácido fólico, un recuento de reticulocitos, un hepatograma y el estudio de la función tiroidea.
Lectura recomendada:
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Journal of Clinical Oncology,
Lectura recomendada:
High Rates of Durable Response are Achieved with Imatinib after Treatment with Interferon (Alpha) plus Cytarabine: Results from the International Randomized Study of Interferon and STI571 (IRIS) Trial
Haematologica,
Lectura recomendada:
Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib
Clinical Cancer Research, 14(17):5325-5331
Lectura recomendada:
Overview of Guidelines on Iron Chelation Therapy in Patients with Myelodysplastic Syndromes and Transfusional Iron Overload
International Journal of Hematology, 88(1):24-29
Lectura recomendada:
Nilotinib: A Second-Generation Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia
Clinical Therapeutics, 30(11):1956-1975
Lectura recomendada:
Therapy Adapted to Molecular Response in Patients with Chronic Myelogenous Leukemia in First Chronic Phase: Results of the Duesseldorf Study
Hematological Oncology, 26(4):213-218
Lectura recomendada:
Oral Rivaroxaban for the Prevention of Symptomatic Venous Thromboembolism after Elective Hip and Knee Replacement
Journal of Bone and Joint Surgery. British Volume, 91(5):636-644
Lectura recomendada:
The Use of Bisphosphonates in Multiple Myeloma: Recommendations of an Expert Panel on Behalf of the European Myeloma Network
Annals of Oncology, 20(8):1303-1317